1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,400 | 23,400 | 12:17 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:47 | JPM Cuts Ascentage Pharma TP to HKD89, Maintains Overweight | 1 | AASTOCKS | ||
| Mo | ASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION SCHEME | 1 | HKEx | ||
| Mo | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Mo | Ascentage Pharma to Present Four Preclinical Advances at AACR 2026 in Poster Sessions | 1 | AASTOCKS | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| Mo | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting | 3 | GlobeNewswire (USA) | ||
| Mo | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS FOUR PROMISING PRECLINICAL STUDIES DEMONSTRATING THE POTENTIAL OF COMBINATION ... | 1 | HKEx | ||
| 13.04. | BTIG reiterates Ascentage Pharma stock rating citing trial readouts | 1 | Investing.com | ||
| 01.04. | ASCENTAGE-B (06855): CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 27.03. | Oppenheimer reiterates Ascentage Pharma stock rating on China growth | 1 | Investing.com | ||
| 27.03. | Wachstum in China: Oppenheimer bestätigt "Outperform"-Rating für Ascentage Pharma | - | Investing.com Deutsch | ||
| 26.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.03. | Ascentage Pharma Group International GAAP EPS of $0.50 beats by $1.66 | 1 | Seeking Alpha | ||
| 26.03. | Ascentage Pharma - B Last Year's Loss Expanded to RMB1.243 Billion | 1 | AASTOCKS | ||
| 26.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates | 198 | GlobeNewswire (Europe) | Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3... ► Artikel lesen | |
| 25.03. | ASCENTAGE-B (06855): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025; AND CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE | 1 | HKEx | ||
| 18.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 18.03. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT DATA FROM FOUR PRECLINICAL STUDIES IN ITS INNOVATIVE PIPELINE AT AMERICAN ASSOCIATION ... | 1 | HKEx | ||
| 13.03. | ASCENTAGE-B (06855): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 11.03. | BTIG initiates Ascentage Pharma stock coverage with buy rating | 1 | Investing.com |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,556 | -1,14 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,150 | 0,00 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| EDITAS MEDICINE | 3,050 | +0,66 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,900 | -1,54 % | H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target | ||
| BASILEA | 61,50 | -0,65 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,940 | -2,35 % | Telix Pharmaceuticals Limited: Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma | MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with... ► Artikel lesen | |
| REPLIGEN | 111,40 | +0,56 % | Repligen Opens Training & Innovation Center in Breda | ||
| UNIQURE | 15,400 | +0,52 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| CODEXIS | 2,252 | +1,44 % | CODEXIS, INC. - 8-K, Current Report | ||
| ORUKA THERAPEUTICS | 60,00 | +2,56 % | Oruka Therapeutics: TD Cowen bestätigt Kaufempfehlung vor wichtigen Studiendaten | ||
| MACROGENICS | 2,940 | -0,68 % | Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics | THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations... ► Artikel lesen | |
| OMEROS | 11,750 | +2,62 % | Omeros erhält permanenten J-Code für TA-TMA-Medikament Yartemlea | ||
| SPERO THERAPEUTICS | 2,290 | -5,14 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 18,130 | +2,34 % | Trader-Interview mit Bastian Galuschka SAP, BASF, ATAIBeckley, Kalvista, MarvellTechnology, Echostar | In dieser Ausgabe des Trader-Interviews analysieren Lothar Albert und Bastian Galuschka die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit speziellem Fokus auf technische Signale, fundamentale... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,540 | -1,67 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 | MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets
MUC16 is highly and stably expressed in the most... ► Artikel lesen |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 21,000 Euro und damit -0,94 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.